Ablatotech Biotherapeutics Company

​Effective Date: 02/12/2025 Last Updated: 3/14/2025

​

1. Acceptance of Terms By applying to participate in the Tarysol clinical trials conducted by Ablatotech, you acknowledge that you have read, understood, and agreed to abide by these Terms of Use. Your application does not guarantee inclusion in the study; final selection is determined after a detailed screening process.

​

2. Purpose of Clinical Trial The Tarysol Clinical Trials aim to evaluate the safety, efficacy, and potential applications of Tarysol, a natural compound designed to rapidly solubilize blood clots in veins. By participating, you contribute to medical research aimed at improving healthcare solutions.

​

3. Voluntary Participation Participation in this trial is entirely voluntary. You may choose to withdraw your application or discontinue your participation in the trial at any time without consequence.

​

4. Eligibility Requirements You must meet the eligibility criteria established for the trial, including but not limited to:

• Age, gender, and health requirements specific to the trial.

• Absence of certain pre-existing medical conditions as determined by our screening questionnaire or health assessments.

 

5. Screening and Selection Applicants will undergo a thorough screening process that includes:

• Completion of detailed questionnaires.

• Submission of medical records and other requested documentation.

• Possible physical and diagnostic evaluations.

• Disclosure of all medications or treatments being used.

Ablatotech reserves the right to decline any applicant who does not meet the trial’s criteria or poses a health risk.

 

6. Privacy and Data Protection Your personal and medical information will be treated as confidential and stored securely. Ablatotech complies with applicable data protection laws such as HIPAA (Health Insurance Portability and Accountability Act) and GDPR (General Data Protection Regulation). Data collected during the trial may be used for research purposes in a de-identified manner.

 

7. Risks and Benefits Participants must understand the following:

• Risks: Use of Tarysol may involve side effects, allergic reactions, or unforeseen adverse events. These will be communicated during the informed consent process.

• Benefits: While personal benefits cannot be guaranteed, participation may contribute to advancements in the treatment of skin disorders.

 

8. Informed Consent You must sign an Informed Consent Form before participating in the trial. This document provides detailed information about the study, its purpose, procedures, potential risks, and benefits.

 

9. Participant Responsibilities By participating in the Tarysol clinical trials, you agree to:

• Follow all instructions provided by the research team.

• Report any side effects, adverse events, or concerns promptly.

• Attend all scheduled visits and comply with study protocols.

Failure to meet these responsibilities may result in removal from the trial.

 

10. Compensation Ablatotech may offer compensation for participation, including reimbursement for travel and related expenses. The details of compensation will be outlined before enrollment.

 

11. Medical Care and Support In the event of injury or adverse effects related to participation in the trial, appropriate medical care will be provided by Ablatotech or its affiliated partners. Details regarding the extent of medical care will be specified in the Informed Consent Form.

 

12. Termination of Participation Ablatotech reserves the right to terminate your participation in the trial if:

• You no longer meet the eligibility requirements.

• You fail to comply with study protocols.

• Continuation in the trial is deemed unsafe or inappropriate.

 

13. Intellectual Property Any discoveries, data, or intellectual property resulting from the clinical trial shall remain the sole property of Ablatotech. Participants have no claim to ownership or compensation beyond what is outlined in this document.

 

14. Limitation of Liability Ablatotech is not liable for any damages beyond those specified in the informed consent, except as required by law.

 

15. Amendments to Terms Ablatotech reserves the right to modify these Terms of Use at any time. Participants will be notified of any significant changes, and continued participation constitutes acceptance of the revised terms.

​

16. International Participation Clinical trials for Tarysol are currently open only to individuals residing outside of the United States. Applicants from international locations will be evaluated under the same rigorous standards as domestic participants.

​

17. Pre-screening medical questionaire Providing answers to the pre-screening medical questionaire is voluntary. If providing that information, you could remain anonymous by not providing your last name.

 

18. Contact Information For questions, concerns, or further information, please contact us at:

• Email: info@ablatotech.com

 

Acknowledgment and Agreement: By submitting an application for the Tarysol clinical trials, you affirm that you have read and understood these Terms of Use and agree to abide by them.